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Hereditary multiple exostosis (HME, also called EXT) is an auto-
somal dominant disorder characterized by the presence of multiple
exostoses (osteochondromas) localized mainly in the juxta-
epiphyseal region of long, tubular bones. These osteochondromas
are apparent during the first decade of life in more than 80% of 
the patients (Solomon, 1963). The estimated prevalence of EXT
ranges from 1.3/100 000 (Hennekam, 1991) to 2/100 000
(Schmale et al, 1994). Penetrance is estimated between 66%
(Suyiura et al, 1976) and 100% (Wicklund et al, 1995). An exo-
stosis can transform into a chondrosarcoma or an osteosarcoma in
about 0.9% to 2.9% of EXT-patients. Other features include short
stature, limb length inequalities, nerve and blood vessel compres-
sion, impaired articular function, bowing of tubular bones and
synostoses (Wicklund et al, 1995). 
EXT is a genetically heterogeneous disease with at least 3
susceptibility loci. 2 of them, the EXT1 gene on chromosome
8q24.1 and the EXT2 gene on chromosome 11p11 have been
isolated by positional cloning (Ahn et al, 1995; Stickens et al,
1996; Wuyts et al, 1996). Since loss of heterozygosity (LOH) has
been observed with markers linked to the EXT1 or EXT2 genes in
both sporadic and exostoses-derived tumour materials, it has been
suggested that the EXT genes might be tumour suppressor genes
(Hecht et al, 1995; Raskind et al, 1995). The EXT3 gene has been
mapped to 19p (Le Merrer et al, 1996). In addition, 3 EXT-like
genes have been mapped, namely EXTL1 on 1p36 (Wise et al,
1997), EXTL2 on 1p11–12 (Wuyts et al, 1997) and EXTL3 on
8p12–22 (Van Hul et al, 1998). They all encode products with the
homologue C-terminals. Although the EXTL genes are considered
strong candidate genes for EXT, most of the EXT patients are
linked with EXT1 and EXT2 and so far no EXTL mutation has
been detected in any EXT patient. 
We now analysed a large Chinese EXT pedigree with at least 38
affected members. After linkage analysis and mutation analysis, a
novel mutation, namely, a deletion of one nucleotide in exon 3 of
the EXT2 gene was observed. 
MATERIALS AND METHODS 
EXT family 
Blood or saliva specimen were collected from 69 members of
a Chinese multigeneration pedigree with hereditary multiple
exostoses with the informed consent of the participants. Among
them, 23 were affected. 
Genomic DNA was extracted from peripheral blood lympho-
cytes by salting-out method (Miller et al, 1988), or from mouth
swabs by Chelex method (Walsh et al, 1991). Mouth swabs were
collected by firm rubbing of a cotton bud backwards and forwards
between the cheek and gum several times (3 cotton buds were used
for each individual). 
Linkage analysis 
Linkage analysis was carried out using the LINKAGE 5.1 package
program MLINK (Lathrop et al, 1984) for 2-point analysis,
assuming dominant inheritance with full penetrance and EXT
frequency set to 1/50 000. Microsatellite repeat markers were
A novel deletion mutation of the EXT2 gene in a large
Chinese pedigree with hereditary multiple exostosis 
CY Xiao1,2, J Wang1,2, SZ Zhang1,2, W Van Hul3, W Wuyts3, WM Qiu1,2, H Wu1,2 and G Zhang1,2
1Department of Medical Genetics, West China Medical Center, Sichuan University, Chengdu, 610041, P. R. China; 2Key Laboratory of Morbid Genomics 
and Forensic Medicine, Sichuan Province, Chengdu, 610041, P. R. China; 3Department of Medical Genetics, University of Antwerp, 2610 Antwerp, 
Belgium 
Summary Hereditary multiple exostoses (EXT) is an autosomal dominant disease characterized by the formation of cartilage-capped
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deletion of a G in exon 3 of EXT2 gene was observed. This deletion co-segregated with the disease phenotype, suggesting that it is the
disease-causing mutation in this family. Furthermore, in at least 4 members chondrosarcoma occurred after either an operation or injury of the
exostosis and 3 of them died of the malignance in the family. Whether the operation or injury was responsible for the malignant transformation
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selected according to literature (Tang et al, 1998). D8S85, D8S285
and D8S199 from 8q24.1 (EXT1), D11S903, D11S1361 and
D11S1355 from 11p11 (EXT2) and D19S221 from 19p(EXT3)
were studied. 
Mutational screening 
After linkage was suggested to the EXT2 gene, exons 2 to 14 of
the EXT2 gene were amplified by using PCR profiles from Wuyts
et al (1998) with slight modification. 
The sequences of the primers were shown in Table 1. Exon 2
was split into 3 overlapping fragments to obtain amplification
products suitable for SSCP analysis. PCR was performed in a 25
ml reaction volume, containing 50–100 ng of genomic DNA, 
1 ´ PCR buffer, 200 mM of each dNTP, 0.4 mM of each primer 
pair, 1.5 mM of MgCl2 and 1 unit of Taq DNA polymerase
(GENETAQ). PCR was carried out in Perkin Elmer 9600 thermal
cycler. After predenaturation at 95°C for 5 min, the PCR was
carried out for 30–35 cycles of denaturation at 94°C for 30 s,
annealing at suitable temperature for 30 s, extension at 72°C for 
30 s, and a final extension at 72°C for 5 min. The annealing
temperature was 55°C for all primer pairs, with the exception of
primer pairs amplifying exons 3, 5 and 10, for which the annealing
temperature was changed to 51°C. The amplified products were
then subjected to agarose gel eletrophoresis to judge their amplifi-
cation efficiency. Finally, SSCP of the amplified products was
performed according to standard protocol, and the gel was silver
stained and analysed. 
The PCR fragments containing aberrant fragments (i.e. exon 3)
were reamplified, and then either purified by use of PCR Clean Up
Kit (Boehringer Mannheim) and directly sequenced by using Cy5
dye-terminator thermal sequenase sequencing kit (Pharmacia
Biotech); or cloned into pGEM T-easy vector (Promega), and the
identified double strand plasmids were then sequenced by using
ABI Prism DNA sequencing kit (PE). Sequencing reactions were
performed according to the instructions by the kit supplier. For
PCR products sequencing, one of the amplification primers for
exon 3 was used as sequencing primer, and sequences were
analysed on ALF express automatic DNA sequencer (Pharmacia
Biotech); for plasmid sequencing, M13 reverse primer was used as
sequencing primer, and sequences were analysed on AB1 377
automatic DNA sequencer (PE). 
RESULTS 
Clinical description of the family 
In the whole family, according to the anamnesis of some family
members, at least 35 individuals were severely affected with
multiple large exostoses, some of them were more than 10 cm in
diameter, 3 (V51, V56 and VI25 in Figure 1) were slightly
affected, with only a isolated small exostosis less than 1 cm in
diameter. Among the severely affected at least in 4 individuals
including the proband (IV53, the first patient observed by doctor
in the family) an exostosis has transformed into chondrosarcoma.
The pedigree is shown in Figure 1. The diagnosis of the disease in
the family was made by osteologists at the First Affiliated Hospital
of West China University of Medical Sciences. Some of the
patients have been confirmed by regional X-radiographic analysis.
In addition, the proband’s diagnosis was made also by biopsy of
Table 1 Primers and related parameters used in the study 
Name Amplified exon Sequence Product length (bp) Annealing temperature 
EXT2-ex2a 2 ctctcccctggtgacc 338 55°C 
EXT2-ex2A8 CACAGCGATAGACATCAAAACACG
EXT2-ex2A26 2 GACAGTCCCATCCCAGAGCGG 249 55°C 
EXT2-ex2A25 GGAGGGAACAAACAGACAGG
EXT2-ex2A4 2 ACTACACTGATGACATCAACCG 176 55°C 
EXT2-ex2b ccctttagttccctgagggcc
EXT2-ex3a 3 gttgacacattaattctccc 184 51°C 
EXT2-ex3b gaacaaaaatgatcttgaaccc
EXT2-ex4a 4 gaataaagtcctttctttctcatcg 205 55°C 
EXT2-ex4b cagtaaaggcacacctggc
EXT2-ex5a 5 gcaattttccaatcacctg 267 51°C 
EXT2-ex5b cctgagcctttgcgagagg
EXT2-ex6a 6 ctagtttgtaatctcttgcctc 222 55°C 
EXT2-ex6b tacgcagaaccactaatgtagag
EXT2-ex7a 7 gggatgtggggctgaaggagg 293 55°C 
EXT2-ex7b ctcctgtccctctgtatccagtc
EXT2-ex8a 8 gcttgctcacttaaaacagc 195 55°C 
EXT2-ex8b gcctcatgtggctagcac
EXT2-ex9a 9 cagctgcttttctgacccg 263 55°C 
EXT2-ex9b gatccagctgagagaggcac
EXT2-ex10a 10 cctcacaaaagttaggag 240 51°C 
EXT2-ex10b aaacacacctgtgtaaaacc
EXT2-ex11a 11 gaatggttgctgtctgaattggg 235 55°C 
EXT2-ex11b ctcagttttgtcaccttgcc
EXT2-ex12a 12 ccccttatttatcagctaaaggg 220 55°C 
EXT2-ex12b caagtgagtggcagagcc
EXT2-ex13a 13 gtccttgacactgacagccagg 175 55°C 
EXT2-ex13b tagagatcagaggctaaggcgc
EXT2-ex14a 14 caaacccctcctccccacctcctc 318 55°C 
EXT2-ex14c GTGGGTTAGGTGGGTGCATGCC
Reverse primers are italicized. Primers located in introns are lower-cased, primers located in exons are capitalized. 178 CY Xiao et al
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the exostosis. Clinically all the severely affected members were of
short stature with mean height of less than 155 cm in male
patients, and had multiple exostoses at the metaphyses of the long
tubular bones, some of them even had 30–40 exostoses all over the
body. The local appearance and radiological findings in some
severely affected members are shown in Figure 2. The proband
noticed her first exostosis of about 1 cm in diameter at her left
pubis when she was 33 years old. The exostosis grew slowly to
about 2 cm 2 years later. Then an operation was performed to
remove this exostosis and biopsy of the removed exostosis was
performed. But 1 year after, the exostosis recurred, grew rapidly
and became painful, then the tumour malignantly transformed to
well-differentiated chondrosarcoma, which was confirmed by
biopsies of the removed tissues at least 7 times during the
following years. The chondrosarcomas then metastasized to the
soft tissues close to spinal column of abdomen and several other
sites in her pelvis, so an extended hemipelvectomy was performed.
In the following 11 years she has had more than 7 operations to
remove the recurred chondrosarcomas. Similarly malignant trans-
formation in another 3 severely affected members had occurred
after accidental injury of one of the exostosis. 
Linkage analysis 
All the 3 markers from 11p11 (EXT2) gave a 2-point LOD-score
value of >3 and showed no recombination between the markers
and the EXT phenotype, therefore the linkage between the 
exostoses and EXT2 gene was firmly established in the large
family. The markers from 8q24 and 19p gave very low 
LOD-score of <1, so the linkage to EXT1 and EXT3 can be
ignored. According to this result, the family’s EXT is linked to
EXT2 was concluded. 
Mutation analysis 
SSCP analysis of exon 3 of all the family members revealed that
all severely affected members showed the same pattern with 2
additional single-strand bands as compared with the unaffected
members and the unrelated healthy members in the family,
suggesting that in the severely affected patients the 2 alleles of the
exon 3 of EXT2 gene are different. However, in 2 of the slightly
affected individuals (V 51 and VI 25), no additional single strand
bands were observed. Figure 3 shows SSCP results of some of the
members in the family. 
Exon 3 of 3 different severely affected members, one slightly
affected member and one unrelated healthy individual were
sequenced. In all the 3 severely affected patients, there was a dele-
tion of ‘G’ at the position 431 of U67357, corresponding to posi-
tion 561 (no. 1 is corresponding to the ‘A’ in the initiation codon in
U64511) in the mRNA sequence (Figure 4). But no such deletion
was observed in the slightly affected member, neither was in the
unrelated healthy individual. 
DISCUSSION 
In the present large family a heterozygous deletion of a ‘G’ in exon
3 of EXT2 gene likely represents the causative defect. It results in
frameshift and premature stop codon that would lead to the
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Figure 1 Pedigree of the present study. Arrow indicates the proband (IV53) (the first patient observed by doctors). All the open boxes represent healthy males,
and open circles healthy females. The half-filled circle (IV11) represents a carrier, i.e., who carries the mutant gene but the phenotype is normal. Boxes or
circles with a crossing line mean that the person has already died A novel mutation of the EXT2 gene in Chinese 179
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expression of a predicted truncated EXT protein with only 281
amino acids, 437 amino acids shorter than the wild-type protein. 
EXT1 and EXT2 genes are putative tumour suppressor genes
(Ahn et al, 1995; Hecht et al, 1995; Raskind et al, 1995). It has
been reported that proteins encoded by these genes, are
endoplasmic reticulum-localized type II transmembrane glyco-
proteins that possess or are tightly associated with glycosyltrans-
ferase activities in the polymerization of heparan sulfate (Lind et
al, 1998; McCormick et al, 2000). EXT2 does not harbour signifi-
cant glycosyltransferase activity in the absence of EXT1. Instead,
Figure 2 Local appearance and radiological findings in two affected members. Large and multiple exostosis around the knee and elbow of IV56 (left) and on
the foot of VI16 (right) 
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Figure 3 SSCP of the exon 3 of EXT2 gene in some of the pedigree members. IV13, V28, V35, VI15, VI16 and VI18 are severely affected patients and IV11 is
a carrier, and in these persons besides the 2 normal single-stranded bands, 2 additional single-stranded bands are observed. The others are healthy members
in the family, in which only 2 single-stranded bands are observed EXT1 and EXT2 form a hetero-oligomeric complex in vivo that
leads to the accumulation of both proteins in the Golgi apparatus.
Remarkably, the Golgi-localized EXT1/EXT2 complex possesses
substantially high glycosyltransferase activity than EXT1 or EXT2
alone, suggesting that the complex represents the biologically rele-
vant form of the enzyme(s). These can easily explain how inher-
ited mutations in either of the two EXT genes can give rise to
hereditary multiple exostoses (McCormick et al, 2000). 
Since the identification of EXT1 and EXT2 genes, there have
been many different mutations reported. Among them at least 49
different EXT1 and 25 different EXT2 mutations have been
detected in EXT patients, and there is evidence that mutations in
these 2 genes are responsible for over 70% of the EXT cases (Wuyts
and Van Hul, 2000). Among the 49 EXT1 mutations, 9 are
nonsense, 21 frameshift and 5 splice site mutations, 2 in-frame dele-
tions with 1 and 5 amino acids respectively, and 12 missense muta-
tions. The 25 EXT2 mutations include 8 nonsense, 11 frameshift, 3
splice site and 3 missense mutations. The deletion of one nucleotide
described in present study has not been described before. 
It is interesting to note that in the studied family, there are 
at least 3 affected members who develop only a single exostosis,
and 2 of them are in their 30s, the third one is 10. In 2 of these 
3 slightly affected patients (V51 and VI25, the third one’s blood
sample was not available), SSCP analysis of exon 3 failed to detect
the same two additional single strand bands as seen in other
severely affected ones. This implies that they might be cases of
phenocopy, or alternatively, the causative gene abnormality in
these 3 individuals may be different from that of the others in the
pedigree, although that 2 different mutations in same family is
scarce. However, whatever the reason is, the interesting feature
makes genetic counselling of the patients more complicated. 
According to the genotype-phenotype correlation, the pene-
trance of EXT in the family is not complete. There is one member
(IV11), whose daughter and granddaughter are affected, carries the
2 additional single strand bands in SSCP, hence the mutation, but
displays no any visible exostoses. 
According to literature, the general recommended treatment to
symptomatic exostoses or dislocated radial heads is to remove
them. Surgery can improve aesthetic appearance and relieve the
pain when done before or after skeletal maturity (Arms et al, 1997;
Porter et al, 2000; Vasseur and Fabre, 2000). It seems that the
tumour does not interfere with the longevity of the patients and
several affected individuals in this family live up to their 80s to
90s. Whether surgical removal of the exostoses is responsible for
the progression to malignancy is not clear. It is possible that some
unknown factors including some modifying genes may play an
important role in the malignant transformation. 
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